October 2008
Although gemcitabine-based chemotherapy is standard in advanced pancreatic cancer, the role of adjuvant chemotherapy is still incompletely defined.
In an oral presentation, Jeffrey A. Zonder, MD, Division of Hematology-Oncology, Karmanos Cancer Center, Wayne State University School of Medicine,Detroit, Michigan, reported updated results of SWOG 0232, a study of lenalidomide (Revlimid) plus dexamethasone compared with dexamethasone alone in patients with newly diagnosed multiple myeloma (MM).
Advertisement
Advertisement
Trending on HCPLive
1
CT Air Trapping Metric May Predict Post-BLVR Pneumothorax Risk
2
Mifepristone Improves HbA1c, Weight in Poorly Controlled T2D, Regardless of GLP-1 Treatment
3
Saroglitazar Targets Bile Acid Dysregulation, Inflammation in PBC, With Raj Vuppalanchi, MD
4
MAESTRO-NASH: Resmetirom May Reduce Cardiovascular Risk in MASH, With or Without Statins
5